You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

~ Buy the KALYDECO (ivacaftor) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR KALYDECO


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Kalydeco

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT01614457 ↗ Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) Completed Cystic Fibrosis Foundation Phase 3 2012-07-01 The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.
NCT01614457 ↗ Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) Completed Cystic Fibrosis Foundation Therapeutics Phase 3 2012-07-01 The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.
NCT01614457 ↗ Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) Completed Vertex Pharmaceuticals Incorporated Phase 3 2012-07-01 The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 3 of 3 entries

Clinical Trial Conditions for Kalydeco

Condition Name

1932002468101214161820Cystic FibrosisChronic Obstructive Pulmonary DiseaseChronic Bronchitis[disabled in preview]
Condition Name for Kalydeco
Intervention Trials
Cystic Fibrosis 19
Chronic Obstructive Pulmonary Disease 3
Chronic Bronchitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

19173002468101214161820Cystic FibrosisFibrosisPulmonary Disease, Chronic Obstructive[disabled in preview]
Condition MeSH for Kalydeco
Intervention Trials
Cystic Fibrosis 19
Fibrosis 17
Pulmonary Disease, Chronic Obstructive 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Kalydeco

Trials by Country

+
Trials by Country for Kalydeco
Location Trials
United States 162
United Kingdom 10
Canada 8
Australia 7
Belgium 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for Kalydeco
Location Trials
Alabama 11
California 9
Massachusetts 9
Illinois 8
Pennsylvania 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Kalydeco

Clinical Trial Phase

20.0%40.0%40.0%00123456Phase 4Phase 3Phase 2[disabled in preview]
Clinical Trial Phase for Kalydeco
Clinical Trial Phase Trials
Phase 4 3
Phase 3 6
Phase 2 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

69.6%26.1%00246810121416CompletedRecruitingNot yet recruiting[disabled in preview]
Clinical Trial Status for Kalydeco
Clinical Trial Phase Trials
Completed 16
Recruiting 6
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Kalydeco

Sponsor Name

trials02468101214Vertex Pharmaceuticals IncorporatedUniversity of Alabama at BirminghamCystic Fibrosis Foundation[disabled in preview]
Sponsor Name for Kalydeco
Sponsor Trials
Vertex Pharmaceuticals Incorporated 13
University of Alabama at Birmingham 6
Cystic Fibrosis Foundation 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

50.0%43.2%6.8%0-2024681012141618202224OtherIndustryNIH[disabled in preview]
Sponsor Type for Kalydeco
Sponsor Trials
Other 22
Industry 19
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

KALYDECO: A Comprehensive Update on Clinical Trials, Market Analysis, and Projections

Introduction to KALYDECO

KALYDECO (ivacaftor) is a groundbreaking medication developed by Vertex Pharmaceuticals for the treatment of cystic fibrosis (CF), a genetic disorder that severely affects the lungs, digestive system, and other organs. Here, we will delve into the clinical trials, market analysis, and future projections for this pivotal drug.

Clinical Trials Overview

Trial 1: STRIVE Study

The STRIVE study was a 48-week, Phase 3, randomized, double-blind, placebo-controlled trial involving 161 patients with CF aged 12 years and older who had the G551D mutation. Key findings included:

  • Significant Improvement in Lung Function: Patients receiving KALYDECO showed a mean absolute improvement in percent predicted forced expiratory volume in one second (ppFEV₁) of +10.6 points at 24 weeks and +10.5 points at 48 weeks compared to the placebo group[1][5].
  • Quality of Life: The Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain score improved by +8.1 points at 24 weeks and +8.6 points at 48 weeks[1].
  • Pulmonary Exacerbations: There was a 60% reduction in the relative risk of pulmonary exacerbations at 24 weeks and a 54% reduction at 48 weeks[1].

Trial 7: Expanded Mutations Study

This 8-week, randomized, double-blind, placebo-controlled, crossover trial involved 246 patients with CF aged 12 years and older with various non-G551D mutations. The study demonstrated:

  • Lung Function Improvement: Significant improvement in ppFEV₁ by Day 15, maintained through 8 weeks[1].
  • Quality of Life: Improvement in the CFQ-R Respiratory Domain score averaged at Weeks 4 and 8[1].

Other Notable Trials

  • A Phase 3 study involving 69 patients with the R117H mutation showed improvements in lung function that persisted for the entire 24-week study duration[3].
  • A Phase 2 combination study with VX-809 (tezacaftor) and KALYDECO in homozygous F508del patients demonstrated statistically significant improvements in lung function, with the highest improvements seen in patients receiving the combination of VX-809 (600mg) and KALYDECO (250mg)[4].

Market Analysis

Current Market Landscape

The cystic fibrosis drugs market is growing rapidly, driven by the increasing prevalence of CF and the development of effective treatments. KALYDECO, being one of the pioneering drugs in this space, has a significant market share.

  • Revenue Forecast: The global cystic fibrosis drugs market is expected to grow substantially from 2024 to 2031, with KALYDECO contributing significantly to this growth due to its efficacy and expanded indications[2].

Regional Market

The market is segmented into regions such as North America, Europe, Asia Pacific, Latin America, and the Rest of the World. North America and Europe are currently the largest markets due to higher awareness and better healthcare infrastructure.

  • Country-Specific Data: Countries like the U.S., Canada, U.K., Germany, and France are key markets, with growing demand in emerging economies like China and India[2].

Competitive Landscape

KALYDECO faces competition from other CFTR modulators and combination therapies, such as those involving tezacaftor and elexacaftor. However, its established efficacy and broad range of approved mutations give it a strong market position.

  • Company Performance: Vertex Pharmaceuticals, the manufacturer of KALYDECO, continues to invest in research and development, expanding the drug's indications and improving its safety profile[2][5].

Market Projections

Growth Trends

The cystic fibrosis drugs market is expected to grow at a significant CAGR from 2024 to 2031, driven by:

  • Increasing Prevalence: Growing awareness and better diagnostic techniques are leading to an increase in diagnosed CF cases.
  • Expanding Indications: KALYDECO has been approved for various mutations, and ongoing research is likely to expand its use further.
  • Combination Therapies: The development of combination therapies involving KALYDECO and other CFTR modulators is expected to enhance its market share[2].

Market Size Estimation

The market size for cystic fibrosis drugs is projected to increase substantially, with KALYDECO being a major contributor.

  • Forecast Estimation: The market is expected to reach several billion dollars by 2031, with KALYDECO maintaining a significant share due to its clinical efficacy and safety profile[2].

Safety and Efficacy

Safety Profile

KALYDECO has an acceptable safety profile, with the most common adverse events being mild to moderate.

  • Transaminase Elevations: One of the notable safety concerns is the elevation of transaminases (ALT or AST), which requires monitoring[1][3].

Efficacy Across Mutations

KALYDECO has shown significant efficacy across various CFTR mutations, including G551D, R117H, and several other gating and missense mutations.

  • Clinical Endpoints: Improvements in lung function, quality of life, and reduction in pulmonary exacerbations have been consistently demonstrated across different studies[1][3][5].

Future Directions

Ongoing Research

Vertex Pharmaceuticals continues to conduct additional clinical studies to expand the indications of KALYDECO and to develop new combination therapies.

  • Combination with Other CFTR Modulators: Studies involving KALYDECO in combination with tezacaftor, ivacaftor, and elexacaftor are ongoing, aiming to treat a broader range of CF mutations[4][5].

Long-Term Effectiveness

There is an ongoing focus on assessing the long-term effectiveness of KALYDECO, particularly in younger patients starting treatment early.

  • Pediatric Studies: Studies in children aged 2 to 5 years are underway to evaluate the long-term benefits of early treatment with KALYDECO[5].

Key Takeaways

  • Clinical Efficacy: KALYDECO has demonstrated significant improvements in lung function, quality of life, and reduction in pulmonary exacerbations across various CFTR mutations.
  • Market Growth: The cystic fibrosis drugs market is expected to grow substantially, with KALYDECO playing a major role due to its established efficacy and expanding indications.
  • Safety Profile: KALYDECO has an acceptable safety profile, although monitoring for transaminase elevations is necessary.
  • Future Directions: Ongoing research aims to expand the drug's indications and assess its long-term effectiveness, particularly in pediatric patients.

FAQs

What is KALYDECO used for?

KALYDECO (ivacaftor) is used to treat cystic fibrosis (CF) in patients with specific mutations in the CFTR gene.

Which mutations is KALYDECO approved for?

KALYDECO is approved for patients with the G551D mutation and several other gating and missense mutations, including R117H and others[1][3][5].

What are the key clinical endpoints improved by KALYDECO?

KALYDECO improves lung function (ppFEV₁), quality of life (CFQ-R Respiratory Domain score), and reduces the risk of pulmonary exacerbations[1][5].

What is the safety profile of KALYDECO?

KALYDECO has an acceptable safety profile, with the most common adverse events being mild to moderate, although it requires monitoring for transaminase elevations[1][3].

What are the future directions for KALYDECO research?

Ongoing research includes studies to expand the indications of KALYDECO, assess its long-term effectiveness, and develop new combination therapies with other CFTR modulators[4][5].

Sources

  1. Kalydeco Clinical Trials - KALYDECO study design and trial data for STRIVE and other studies[1].
  2. Cystic Fibrosis Drugs Market and Forecast - iHealthcareAnalyst report on the cystic fibrosis drugs market[2].
  3. Summary Basis of Decision for Kalydeco - Health Canada's review of Kalydeco's benefit/risk profile[3].
  4. Final Data from Phase 2 Combination Study of VX-809 and KALYDECO - Vertex Pharmaceuticals' press release on the study results[4].
  5. Kalydeco | European Medicines Agency (EMA) - EMA's assessment of Kalydeco's efficacy and safety[5].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.